Gefitinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9281 publications
3-Formylchromone attenuates urethane-induced lung carcinogenesis and enhances gefitinib anti-tumor response via modulation of IL-6/JAK1/STAT3/cyclin D1 signaling.
Journal: Toxicology mechanisms and methods
Published: April 11, 2026
Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.
Journal: Future science OA
Published: April 04, 2026
Triple-Dose Furmonertinib for Leptomeningeal Metastases in Advanced Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report.
Journal: Cureus
Published: February 23, 2026
The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 16, 2026
Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.
Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.
Journal: Journal of clinical medicine
Published: February 16, 2026
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 as a Biomarker for Predicting Response to Erlotinib and Gefitinib in Lung Adenocarcinoma: An Integrative Analysis of Transcriptomic Data of PC-9 and Drug-Resistant PC-9 Cell Lines.
Journal: International journal of molecular sciences
Published: February 11, 2026
Expression of Concern: The Transcription Factor FOXO3a is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells.
Journal: Molecular cancer therapeutics
Published: February 05, 2026
Expression of Concern: Gefitinib (Iressa) Represses FOXM1 Expression via FOXO3a in Breast Cancer.
Journal: Molecular cancer therapeutics
Published: February 05, 2026
New quinazolinone-thiazolidinedione hybrids as selective anti-lung cancer agents and promising EGFR inhibitors.
Journal: Future medicinal chemistry
Published: February 04, 2026
Cost-effectiveness analysis of rezivertinib and gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: February 03, 2026
Endocyclic Trisubstituted Hydroxylamine Isosteres of Basic Amines for ADME Modulation and Reduction of hERG Activity.
Journal: ACS medicinal chemistry letters
Published: January 30, 2026
FOXK2/SH2D3A axis recruits EGFR to drive papillary thyroid cancer progression and confers sensitivity to EGFR inhibition.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: January 25, 2026
Last Updated: 04/28/2026